# Bisphosphonates

Bisphosphonates are bone drugs that copy a natural molecule (pyrophosphate) and stick tightly to the mineral in your bones. When bone-dissolving cells (osteoclasts) chew on that bone, they swallow the drug. The nitrogen-containing types (alendronate, zoledronate, risedronate) then jam an enzyme inside the osteoclast. That enzyme is farnesyl diphosphate synthase, part of the mevalonate pathway. Blocking it cripples the cell and shortens its life. These drugs are approved for osteoporosis, Paget's disease, high blood calcium from cancer, and bone metastases. They clearly cut fracture risk. Some data also hint at broader anti-aging effects. In a trial in people who had recently broken a hip, yearly intravenous zoledronate was linked to lower overall death rates (the HORIZON Recurrent Fracture Trial; Lyles et al., 2007, NEJM). Several studies also tie these drugs to fewer breast, colorectal, and possibly other cancers, though hidden confounding cannot be ruled out. Aging researchers are curious about a senolytic-like effect. The drugs deplete osteoclast precursors and might clear out some calcification-linked senescent cells. For now that is just a hypothesis in humans. Side effects include irritation of the esophagus, a rare jawbone problem (osteonecrosis of the jaw, mostly with high-dose IV use), and unusual thigh-bone fractures after long-term use.

## Sources

- Lyles KW, Colón-Emeric CS, Magaziner JS et al.. (2007). Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture (HORIZON Recurrent Fracture Trial). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa074941

---

_Canonical: https://longevity-switzerland.com/en/glossary/bisphosphonates · Part of Longevity Cities · Updated 2026-06-22_